HE3177
/ Harbor Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 18, 2020
Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer.
(PubMed, Tumori)
- "In 93 (2.9%) of the 3177 doses, 1 episode of irAEs was experienced...With the increased use of immunotherapeutic agents, increased awareness and early recognition are required for effective management of irAEs. Our experience as a single institution might be of use for health care providers in oncology."
Adverse events • Checkpoint inhibition • Clinical • Journal • Endocrine Disorders • Hepatology • Immune Modulation • Inflammation • Oncology • Pneumonia
1 to 1
Of
1
Go to page
1